Biopharma industry updates on COVID-19 treatments progress and warns about upholding regulatory standards of quality
On 3rd September, CEOs from five companies – Pfizer, Roche, MSD, Gilead, and Lilly took part in the latest IFPMA COVID-19 virtual media briefing dedicated to the on-going efforts to find a treatment for COVID-19. During the course of the pandemic, we have witnessed a remarkable show of solidarity, partnership, and collaboration within the industry...
Read moreSpeeding up the search for safe and effective COVID-19 therapies & vaccines – joining forces for a challenging road ahead
Last week, high-level representatives from seven companies – Takeda, Merck, AstraZeneca, CSL Behring, MSD, Pfizer and Sandoz – took part in a second IFPMA COVID-19 virtual media briefing dedicated to the on-going R&D efforts to find a treatment for COVID-19. It was an important milestone, taking stock of all that has been achieved in little...
Read morePharma delivers COVID-19 solutions, but calls for the dilution of intellectual property rights are counterproductive
8 December 2020, Geneva — The biopharmaceutical industry has made the fight against the COVID-19 pandemic its top priority, devoting its resources, expertise, know-how, and intellectual assets to developing potential treatments, diagnostics and vaccines at unprecedented pace, while committing to and engaging in new levels of international collaboration and coordination through initiatives such as ACT-A,...
Read moreIFPMA Statement at the 22nd WHO Expert Committee Meeting on the Selection and Use of Essential Medicines
Delivered by Greg Perry, Assistant Director General, IFPMA IFPMA welcomes the opportunity to address this meeting of the EML Expert Committee, and we take this occasion to also congratulate WHO for the progress made over forty-two years in the iterations of the Essential Medicines List. IFPMA represents over 30 leading global biopharmaceutical companies and...
Read moreGovernment and Life Science Industry Join Forces on 100 Days Mission for Future Pandemics
Landmark collaboration between Government and life sciences industry leaders to join mission to protect against future pandemic threats and slash time to develop and deploy new diagnostics, therapeutics and vaccines to 100 days. Intention to work towards the ambition of a 100 Days Mission follows crucial discussions at UK-hosted G7 Health Ministers’ and life sciences...
Read moreThe evolution of the SARS-COV-2 virus is a stark reminder that research and innovation must continue (Step #5)
Developing COVID-19 vaccines in less than a year was a monumental achievement – but to improve the efficacy, manufacture and distribution of vaccines and combat emerging variants, governments, regulators and research scientists must work together to drive further innovation. Imagine if scientists invented a COVID-19 vaccine that can be given orally, without the need of...
Read moreInnovative biopharmaceutical industry comment on COVID-19 vaccines dosing strategies and recommend following the science
IFPMA, PhRMA, EFPIA, Vaccines Europe, BIO, ICBA Statement With the first COVID-19 vaccines authorized by regulatory authorities and administered to the public, the biopharmaceutical industry, including leading vaccine makers, recognize that a critical new phase of the COVID-19 pandemic has begun. Collaboration among the global community has resulted in safe and efficacious vaccines being authorized...
Read moreCOVID-19 Biopharmaceutical Industry – Regulatory Guiding Principles (May 2021)
On 14 May 2020, we released our first Regulatory Guiding Principles in the unprecedented and unknown context of the COVID-19 pandemic. One year on and we are still facing the impact of this public health emergency, yet we have seen many advancements and successes.
Read moreThe road to building trust in COVID-19 vaccines
This oped was originally published on Media Planet Vaccine Awareness Campaign on 22 December 2020 Vaccines are one of the most cost effective interventions we have to safeguard public health and yet during this pandemic we have seen a decrease in public confidence. The latest World Economic Forum/Ipsos survey found that the number of people...
Read moreApplying lessons learned on regulatory agility: Perspectives from national regulatory authorities
Regulatory agility played a crucial role in speeding up the development and approval of medicines and vaccines during the COVID-19 pandemic. The insights gained from this success are valuable for continually strengthening regulatory frameworks, both in emergency and non-emergency situations. IFPMA collaborated with external researchers to gather insights from national regulatory authorities and pharmaceutical companies on the success factors behind regulatory agility, especially ahead of future pandemics.
Read more